Referencias bibliográficas

La DISFUNCIÓN MITOCONDRIAL Y LA DEFICIENCIA MICRONUTRICIONAL, DOS FACTORES COMUNES EN LA INSUFICIENCIA CARDIACA

  1. Azizi-Namini P, Ahmed M, Yan AT, Keith M. The role of B vitamins in the management of heart failure. Nutr Clin Pract. 2012 Jun;27(3):363-74.
  2. van der Wal HH, Grote Beverborg N, Dickstein K, Anker SD, Lang CC, Ng LL, et al. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. Eur Heart J. 2019;40(44):3616–25.
  3. Cicero AFG, Colletti A, von Haehling S, Vinereanu D, Bielecka-Dabrowa A, Sahebkar A, et al. Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). Nutr Res Rev. 2020;33(1):155–79.
  4. Bomer N, Pavez-Giani MG, Grote Beverborg N, Cleland JGF, van Veldhuisen DJ, van der Meer P. Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism? J Intern Med. 2022 Feb 9.
  5. Reinecke F, Smeitink JAM, van der Westhuizen FH. OXPHOS gene expression and control in mitocondrial disorders. Biochim Biophys Acta – Mol Basis Dis. 2009;1792(12):1113–21.
  6. Dominic EA, et al. Mitochondrial cytopathies and cardiovascular disease. Heart. 2014 Apr;100(8):611-8.
  7. Kraus B, Cain H. Giant mitochondria in the human myocardium–morphogenesis and fate. Virchows Arch B Cell Pathol Incl Mol Pathol. 1980;33(1):77-89
  8. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci. 2001 Mar;114(Pt 5):867-74.
  9. Stadhouders AM, et al. Mitochondrial creatine kinase: a major constituent of pathological inclusions seen in mitochondrial myopathies. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5089-93.
  10. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):808-13.
  11. Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018 Aug 31;128(9):3716-3726
  12. Pound KM, et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res. 2009 Mar 27;104(6):805-12.
  13. Pereira RO, et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc. 2013 Sep 19;2(5):e000301.
  14. Finley LW, Haas W, Desquiret-Dumas V, Wallace DC, Procaccio V, Gygi SP, Haigis MC. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One. 2011;6(8):e23295.
  15. Horton JL, et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight. 2016 Feb;2(1):e84897.
  16. Zhang X, Ji R, et al. MicroRNA-195 Regulates Metabolism in Failing Myocardium Via Alterations in Sirtuin 3 Expression and Mitochondrial Protein Acetylation. Circulation. 2018 May 8;137(19):2052-2067.
  17. Diguet N, et al. Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. Circulation. 2018 May 22;137(21):2256-2273.
  18. Lee CF, et al. Normalization of NAD+ Redox Balance as a Therapy for Heart Failure. Circulation. 2016 Sep 20;134(12):883-94.
  19. Wang W, Karamanlidis G, Tian R. Novel targets for mitochondrial medicine.Sci Transl Med. 2016; 8:326rv3.
  20. Abdellatif M, Sedej S, Kroemer G. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation. 2021 Nov 30;144(22):1795-1817.
  21. Liu L, Su X, Quinn WJ III, Hui S, Krukenberg K, Frederick DW, Redpath P, Zhan L, Chellappa K, White E, et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 2018;27:1067–1080.e5.
  22. Mori V, Amici A, Mazzola F, Di Stefano M, Conforti L, Magni G, Ruggieri S, Raffaelli N, Orsomando G. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. PLoS One. 2014;9:e113939.
  23. Zhang YJ, Zhang M, Zhao X, Shi K, Ye M, Tian J, Guan S, Ying W, Qu X. NAD+ administration decreases microvascular damage following cardiac ischemia/reperfusion by restoring autophagic flux. Basic Res Cardiol. 2020;115:57.
  24. Ait-Aissa K, et al. Mitochondrial Oxidative Phosphorylation defect in the Heart of Subjects with Coronary Artery Disease. Sci Rep. 2019 May 20;9(1):7623.
  25. Van Opbergen CJM, den Braven L, Delmar M, van Veen TAB. Mitochondrial Dysfunction as Substrate for Arrhythmogenic Cardiomyopathy: A Search for New Disease Mechanisms. Front Physiol. 2019 Dec
  26. McKeag NA, McKinley MC, Harbinson MT, McGinty A, Neville CE, Woodside JV, et al. Dietary micronutrient intake and micronutrient status in patients with chronic stable heart failure. J Cardiovasc Nurs. 2017;32(2):148–55.
  27. Keith ME, Walsh NA, Darling PB, Hanninen SA, Thirugnanam S, Leong-Poi H, Barr A, Sole MJ. B-vitamin deficiency in hospitalized patients with heart failure. J Am Diet Assoc. 2009 Aug;109(8):1406-10.
  28. Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol. 2006 Jan 17;47(2):354-61. doi: 10.1016/j.jacc.2005.08.060. PMID: 16412860.
  29. Hu Z, Mao L, Wang L. Levels of Serum IGF-1, HCY, and Plasma BNP in Patients with Chronic Congestive Heart Failure and Their Relationship with Cardiac Function and Short-Term Prognosis. Evid Based Complement Alternat Med. 2022 Aug 23;2022:4118976.
  30. Al-Mubarak AA, van der Meer P, Bomer N. Selenium, selenoproteins, and heart failure: current knowledge and future perspective. Curr Heart Fail Rep. 2021;18:122–31.
  31. Schomburg L, Orho-Melander M, Struck J, Bergmann A, Melander O. Selenoprotein-P deficiency predicts cardiovascular disease and death. Nutrients 2019;11:1852.
  32. Bomer N, Grote Beverborg N, Hoes MF, Streng KW, Vermeer M, Dokter MM, et al. Selenium and outcome in heart failure. Eur J Heart Fail. 2020;22(8):1415–23.
  33. van der Pol A, van GilstWH, Voors AA, van der Meer P. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019;21:425–35.
  34. Zhang L, Gao Y, Feng H, Zou N, Wang K, Sun D. Effects of selenium deficiency and low protein intake on the apoptosis through a mitochondria-dependent pathway. J Trace Elem Med Biol. 2019;56:21–30.
  35. Cohen N, Golik A. Zinc balance and medications commonly used in the management of heart failure. Heart Fail Rev. 2006;11(1):19–24.
  36. Rosenblum H, Wessler JD, Gupta A, Maurer MS, Bikdeli B. Zinc deficiency and heart failure: a systematic review of the current literature. J Card Fail. 2020;26(2):180–9.
  37. Quirós PM, Langer T, López-Otín C. New roles for mitochondrial proteases in health, ageing and disease. Nat Rev Mol Cell Biol. 2015;16(6):345–59.
  38. Singal PK, Kirshenbaum LA. A relative deficit in antioxidant reserve may contribute in cardiac failure. Can J Cardiol. 1990;6(2):47–9.
  39. Xu Z, Zhou J. Zinc and myocardial ischemia/reperfusion injury. BioMetals 2013;26(6):863–78.
  40. Ford ES. Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol. 2000;151(12):1182–8.
  41. Grammer TB, Kleber ME, Silbernagel G, Pilz S, Scharnagl H, Lerchbaum E, et al. Copper, ceruloplasmin, and long-term cardiovascular and total mortality (The Ludwigshafen Risk and Cardiovascular Health Study). Free Radic Res. 2014;48(6):706–15.
  42. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA. 1985;82(3):901–4.
  43. Alehagen U, Aaseth J, Johansson P. Reduced cardiovascular mortality 10 years after supplementation with selenium and coenzyme Q10 for four years: follow-Up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens. PLoS One 2015;10(12):e0141641
  44. Cascino TM, Hummel SL. Nutrient deficiencies in heart failure: a micro problem with macro effects? J Am Heart Assoc. 2018;7(17):e010447
  45. Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019;25(5):380–400.
  46. Witte KKA, Nikitin NP, Parker AC, von Haehling S, Volk H-D, Anker SD, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005;26(21):2238–44
  47. Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143(6):1092–100
  48. Fumagalli S, et al. Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol. 2011 Apr;34(4):211-7.
  49. Xu X, et al. Pyrroloquinoline quinone can prevent chronic heart failure by regulating mitochondrial function. Cardiovasc Diagn Ther. 2020 Jun;10(3):453-469.
  50. Garakyaraghi M, Bahrami P, Sadeghi M, Rabiei K. Combination effects of seleniumand coenzyme Q10 on left ventricular systolic function in patients with heart failure. Iran Hear J. 2015;15(4):6–12.
  51. Dudek M., Knutelska J., Bednarski M., et al. Alpha lipoic acid protects the heart against myocardial post ischemia-reperfusion arrhythmias via KATP channel activation in isolated rat hearts. Pharmacological Reports. 2014;66(3):499–504.
  52. Tian Y.-F., He C.-T., Chen Y.-T., Hsieh P.-S. Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. World Journal of Gastroenterology. 2013;19(18):2761–2771.
  53. Gomes M., Negrato C. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetology & Metabolic Syndrome. 2014
  54. Li C.-J., Zhang Q.-M., Li M.-Z., Zhang J.-Y., Yu P., Yu D.-M. Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression of mitochondrial oxidative stress to reduce diabetic cardiomyopathy. Chinese Medical Journal. 2009;122(21):2580–2586.
  55. Abdellatif M, Trummer-Herbst V, Koser F, Durand S, Adao R, Vasques-Novoa F, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med. (2021) 13:eabd7064